Product
ECT-001-CB
Aliases
Conditioning Regimen (Alternative): MIDI: fludarabine: 30 mg/m2/day IV x 5 days, cyclophosphamide: 50 mg/kg IV , thiotepa: 5 mg/kg/day IV x 2 days , TBI: 400 cGy, Conditioning Regimen (Preferred): clofarabine:30 mg/m2/day IV x 4 days, fludarabine:10 mg/m2/day IV x 4 days, busulfan: daily for 4 days with cumm Bu target = 90mg h/L, ECT-001-CB (UM171-Expanded Cord Blood Transplant), GVHD Prophylaxis: Tacrolimus/MMF
2 clinical trials
3 indications
Indication
High-Risk Myeloid MalignanciesIndication
Cord Blood TransplantIndication
High Risk Hematological MalignancyClinical trial
An Open-label, Multi-center, Phase I/II Study of MFA-370 in Patients With Metastatic Urothelial CancerStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Open-Label Study of UM171-Expanded Cord Blood Transplantation in Patients With High and Very High Risk Acute Leukemia/MyelodysplasiaStatus: Active (not recruiting), Estimated PCD: 2026-02-01